{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:43:36Z","timestamp":1791960216435,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Doc Ophthalmol"],"published-print":{"date-parts":[[2002,3]]},"DOI":"10.1023\/a:1014644307518","type":"journal-article","created":{"date-parts":[[2002,12,28]],"date-time":"2002-12-28T16:18:52Z","timestamp":1041092332000},"page":"151-170","source":"Crossref","is-referenced-by-count":54,"title":["Visual field constriction and electrophysiological changes associated with vigabatrin"],"prefix":"10.1007","volume":"104","author":[{"given":"Dorothea","family":"Besch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Kurtenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckart","family":"Apfelstedt-Sylla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Sadowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Dennig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Asenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhart","family":"Zrenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Schiefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"360510_CR1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","volume":"314","author":"T Eke","year":"1997","unstructured":"Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997; 314: 180\u2013181","journal-title":"Br Med J"},{"key":"360510_CR2","first-page":"1694","volume":"314","author":"GFA. Harding","year":"1997","unstructured":"Harding GFA. Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist. Br Med J 1997; 314: 1694","journal-title":"Br Med J"},{"key":"360510_CR3","first-page":"1694","volume":"314","author":"N Blackwell","year":"1997","unstructured":"Blackwell N, Hayllar J, Kelly G. Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing. Br Med J 1997; 314: 1694","journal-title":"Br Med J"},{"key":"360510_CR4","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/bmj.314.7095.1693a","volume":"314","author":"EA Wilson","year":"1997","unstructured":"Wilson EA, Brodie MJ. Chronic refractory epilepsy may have role in causing these unusual lesions. Br Med J 1997, 314: 1693","journal-title":"Br Med J"},{"key":"360510_CR5","first-page":"1694","volume":"314","author":"IC Wong","year":"1997","unstructured":"Wong IC, Mawer GE, Sander JW. Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent. Br Med J 1997; 314: 1694","journal-title":"Br Med J"},{"key":"360510_CR6","first-page":"233","volume":"316","author":"R MacKenzie","year":"1998","unstructured":"MacKenzie R, Klistorner A. Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin. Br Med J 1998; 316: 233","journal-title":"Br Med J"},{"key":"360510_CR7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/bmj.316.7126.232","volume":"316","author":"GFA. Harding","year":"1998","unstructured":"Harding GFA. Severe persistent visual field constriction associated with vigabatrin. Benefit:risk ratio must be calculated for individual patients. Br Med J 1998; 316: 232\u20133","journal-title":"Br Med J"},{"key":"360510_CR8","first-page":"206","volume":"317","author":"GP Rao","year":"1998","unstructured":"Rao GP, Fat FA, Kyle G, Leach JP, Chadwick DW, Batterbury M. Study is needed of visual field defects associated with any long term antiepileptic drug. Br Med J 1998; 317: 206","journal-title":"Br Med J"},{"key":"360510_CR9","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0140-6736(05)79254-0","volume":"352","author":"M Baulac","year":"1998","unstructured":"Baulac M, Nordmann JP. Lano\u00e9 Y. Severe visual field constriction and side effects of GABA-mimetic antiepileptic agents. Lancet 1998; 352:546","journal-title":"Lancet"},{"key":"360510_CR10","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/S0161-6420(99)90345-7","volume":"106","author":"H Daneshvar","year":"1999","unstructured":"Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D. Symptomatic and asymptomatic visual field loss in patients taking vigabatrin. Ophthalmology 1999; 106: 1792\u20138","journal-title":"Ophthalmology"},{"issue":"9","key":"360510_CR11","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1212\/WNL.53.9.2082","volume":"53","author":"NR Miller","year":"1999","unstructured":"Miller NR, Johnson MA, Paul SR. Girkin CA, Perry JD, Endres M, Krauss GL. Visual dysfunction in patients receiving vigabatrin - clinical and electrophysiologic findings. Neurology 1999; 53(9): 2082\u20137","journal-title":"Neurology"},{"key":"360510_CR12","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1212\/WNL.52.8.1713","volume":"52","author":"S Vanhatalo","year":"1999","unstructured":"Vanhatalo S, P\u00e4\u00e4kk\u00f6nen L. Visual field constriction in children treated with vigabatrin. Neurology 1999; 52: 1713\u20134","journal-title":"Neurology"},{"key":"360510_CR13","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/WNL.53.5.922","volume":"53","author":"R K\u00e4lvi\u00e4inen","year":"1999","unstructured":"K\u00e4lvi\u00e4inen R, Nousiainen I. M\u00e4ntyj\u00e4rvi M, Nikoskelainen E, Partanen J, Partanen K, Riekkkinen P. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53: 922\u20136","journal-title":"Neurology"},{"key":"360510_CR14","doi-asserted-by":"crossref","unstructured":"Lawden MC, Eke T, Degg C, Harding GF, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999; 716\u201322","DOI":"10.1136\/jnnp.67.6.716"},{"issue":"12","key":"360510_CR15","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/j.1528-1157.1999.tb01599.x","volume":"40","author":"JM Wild","year":"1999","unstructured":"Wild JM, Martinez C, Reinshagen G, Harding GF. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999; 40(12): 1784\u201394","journal-title":"Epilepsia"},{"key":"360510_CR16","unstructured":"Besch D, Safran NB, Matter MA, Asenbauer C, Dennig D, Zrenner E, Schiefer U. What is specific about vigabatrin-induced visual field defects? Submitted to Ann Neurol."},{"key":"360510_CR17","first-page":"1694","volume":"314","author":"JT Backstrom","year":"1997","unstructured":"Backstrom JT, Hinkle RI, Flicker MR. Manufacturers have started several studies. Br Med J 1997; 314: 1694\u20135","journal-title":"Br Med J"},{"issue":"Suppl","key":"360510_CR18","first-page":"256","volume":"40","author":"CF Arndt","year":"1999","unstructured":"Arndt, CF, Derambure P, Defoort S, Hache JC. Is visual impairment related to vigabatrin reversible? Epilepsia 1999; 40(Suppl): 256","journal-title":"Epilepsia"},{"key":"360510_CR19","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0140-6736(99)02095-4","volume":"354","author":"M Versino","year":"1999","unstructured":"Versino M, Veggiotti P. Reversibility of vigabatrin-induced visual-field defect. The Lancet 1999; 354: 486","journal-title":"The Lancet"},{"issue":"143","key":"360510_CR20","first-page":"148","volume":"15","author":"WH Butler","year":"1987","unstructured":"Butler WH, Ford GP, Newberne JW. A study of the effects of vigabatrin on the central nervous system and retina of sprague dawley and lister-hooded rats. Toxicol Pathol 1987; 15:143: 148","journal-title":"Toxicol Pathol"},{"key":"360510_CR21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1528-1157.1989.tb05827.x","volume":"30","author":"WH. Butler","year":"1989","unstructured":"Butler WH. The neuropathology of vigabatrin. Epilepsia 1989; 30: 515\u20137","journal-title":"Epilepsia"},{"key":"360510_CR22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/019262339001800201","volume":"18","author":"JP Gibson","year":"1990","unstructured":"Gibson JP, Yarrington JT, Loudy DE. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 1990; 18: 225\u201338.","journal-title":"Toxicol Pathol"},{"key":"360510_CR23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/WNL.46.1.54","volume":"46","author":"J French","year":"1996","unstructured":"French J, Mosier M, Walker S, Somerville K, Sussman N. A double-blind placebo controlled study of vigabatrin 32 g\/day in patients with uncontrolled complex partial seizures. Neurology 1996; 46: 54\u201361","journal-title":"Neurology"},{"key":"360510_CR24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/1059-1311(92)90019-W","volume":"1","author":"J Cocito","year":"1992","unstructured":"Cocito J, Maffini M, Loeb C. MRI findings in epileptic patients on vigabatrin for more than five years. Seizure 1992; 1: 163\u20135","journal-title":"Seizure"},{"key":"360510_CR25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1528-1157.1997.tb01121.x","volume":"38","author":"F Mauguiere","year":"1997","unstructured":"Mauguiere F, Chauvel P, Dewailly J, Dousse N. No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicenter Group. Epilepsia 1997; 38: 301\u20138","journal-title":"Epilepsia"},{"key":"360510_CR26","first-page":"817","volume":"116","author":"K R\u00fcther","year":"1998","unstructured":"R\u00fcther K, Pung T, Keliner U, Schmitz B, Hartmann C, Seeliger M. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol 1998; 116: 817\u20139","journal-title":"Arch Ophthalmol"},{"key":"360510_CR27","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1212\/WNL.50.3.614","volume":"50","author":"GL Krauss","year":"1998","unstructured":"Krauss GL, Johnson MA, Miller NR. Vigabatrin associated retinal cone system dysfunction. Electroretinogram and ophthalmologic findings. Neurology 1998; 50: 614\u20138","journal-title":"Neurology"},{"key":"360510_CR28","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1212\/WNL.52.6.1201","volume":"52","author":"CF Arndt","year":"1999","unstructured":"Arndt CF, Derambure P, Defoort-Dhellemmes S, Hache JC. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 1999; 52: 1201\u20135","journal-title":"Neurology"},{"issue":"Suppl","key":"360510_CR29","first-page":"427","volume":"31","author":"A Bayer","year":"1990","unstructured":"Bayer A, Zrenner E, Reid S, Schmidt D. Effects of anticonvulsant drugs on retinal function. Psychophysical and electrophysiological findings on patients with epilepsy. Invest Ophthalmol Vis Sci 1990; 31(Suppl):427","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"360510_CR30","first-page":"89","volume":"66","author":"AU Bayer","year":"1995","unstructured":"Bayer AU, Thiel HJ, Zrenner E, Paulus W. Ried S, Schmidt D. Disorders of color reception and increased glare sensitivity in phenytoin and carbamazepine therapy: ocular side effects of anticonvulants. Nervenarzt 1995; 66: 89\u201396","journal-title":"Nervenarzt"},{"key":"360510_CR31","first-page":"471","volume-title":"Perimetry Update 1996\/1997","author":"TJ Dietrich","year":"1997","unstructured":"Dietrich TJ, Friedrich M, Selig B, Benda N, Schiefer U. Application of video display units for campimetric purposes \u2013luminance characteristics and calibration procedures. In: Wall M, Heijl A, eds. Perimetry Update 1996\/1997. Amsterdam\/New York: Kugler Publications, 1997: 471"},{"issue":"Suppl1","key":"360510_CR32","first-page":"141","volume":"94","author":"TJ Dietrich","year":"1997","unstructured":"Dietrich TJ, Schiefer U, Benda N, Selig B. Autokinetische Perimetrie bei Patienten mit Retinitis pigmentosa. Ophthalmologe 1997; 94(Suppl 1): 141","journal-title":"Ophthalmologe"},{"issue":"Suppl1","key":"360510_CR33","first-page":"176","volume":"94","author":"U Schiefer","year":"1997","unstructured":"Schiefer U, Dietrich TJ. Benda N. Autokinetische Perimetrie\/Kampimetrie \u2013 Prinzip und Einsatzbeispiele. Ophthalmologe 1997; 94(Suppl 1): 176","journal-title":"Ophthalmologe"},{"key":"360510_CR34","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1001\/archopht.1989.01070010838024","volume":"107","author":"MF Marmor","year":"1989","unstructured":"Marmor MF, Arden GB, Nilsson SE, Zrenner E. Standard for clinical electroretinography. Arch Ophthalmol 1989; 107: 816\u20139","journal-title":"Arch Ophthalmol"},{"key":"360510_CR35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1023\/A:1002016531591","volume":"97","author":"ML Marmor","year":"1999","unstructured":"Marmor ML, Zrenner E. Standard for clinical electroretinography (1999 update). Doc Ophthalmol 1999; 97: 143\u201356","journal-title":"Doc Ophthalmol"},{"key":"360510_CR36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archopht.1993.01090050035023","volume":"111","author":"ML Marmor","year":"1993","unstructured":"Marmor ML, Zrenner E. Standard for clinical electro-oculography. Arch Ophthalmol 1993; 111: 601\u20134","journal-title":"Arch Ophthalmol"},{"key":"360510_CR37","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0042-6989(92)90235-B","volume":"32","author":"EE Sutter","year":"1992","unstructured":"Sutter EE, Tran D. The field topography of ERG components in man. I. The photopic luminance response. Vis. Res 1992; 32: 433\u201346","journal-title":"Vis. Res"},{"key":"360510_CR38","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1017\/S0952523800006696","volume":"12","author":"S Wu","year":"1995","unstructured":"Wu S, Sutter EE. A topographic study of oscillatory potentials in man. Vis Neurosci 1995; 12: 1013\u201325","journal-title":"Vis Neurosci"},{"key":"360510_CR39","unstructured":"Kurtenbach A, Langrova H, Zrenner B. Multifocal oscillatory potentials in Type 1 diabetics without retinopathy. Invest Ophthalmol Vis Sci (in press)"},{"key":"360510_CR40","unstructured":"Martinez C, Rietbrock S. Visual field defects: pattern and epidemiology. ISCEV Feb. 2000, Sydney."},{"issue":"4","key":"360510_CR41","first-page":"4743","volume":"41","author":"D Besch","year":"2000","unstructured":"Besch D, Safran AB, Kurtenbach A, Apfelstedt-Sylla E, Dietrich TJ, Asenbauer C, Dennig D, Zrenner B, Schiefer U. Visual field defects and inner retinal dysfunction associated with vigabatrin. Invest Ophthalmol Vis Sci 2000; 41(4): 4743","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"360510_CR42","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s004150050165","volume":"10","author":"K Crofts","year":"1997","unstructured":"Crofts K, Brennan R, Kearney P, O'Connor G. Vigabatrin induced optic neuropathy. J Neurol 1997; 10: 666\u20137","journal-title":"J Neurol"},{"key":"360510_CR43","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1528-1157.1999.tb02066.x","volume":"40","author":"GR Mirchandani","year":"1999","unstructured":"Mirchandani GR, Abi-Saab W, Mattson RH, Kross JD. Garbapentin and Vigabatrin enhance promoted GABA release in rat hippocampus in vivo. Epilepsia 1999, 40: 138","journal-title":"Epilepsia"},{"key":"360510_CR44","first-page":"244","volume":"40","author":"GJ Sills","year":"1999","unstructured":"Sills GJ, Patsalos PN, Butler B, Ratnaraj N, Brodie MJ. Concentration-related pharmacodynamic study of vigabatrin and tiagabine in rat brain and eye. Epilepsia 1999; 40: 244","journal-title":"Epilepsia"},{"issue":"Suppl2","key":"360510_CR45","first-page":"6","volume":"39","author":"RG Beran","year":"1998","unstructured":"Beran RG, Currie J, Dandbach J, Plunkett M. Visual field restriction with new antiepileptic medication. Epilepsia 1998; 39(Suppl 2): 6","journal-title":"Epilepsia"},{"issue":"Suppl","key":"360510_CR46","first-page":"259","volume":"40","author":"R K\u00e4lvi\u00e4inen","year":"1999","unstructured":"K\u00e4lvi\u00e4inen R, Nousiainen I, M\u00e4ntyjarvi M, Riekkkinen P. Absence of concentric visual field defects in patients with initial tiagabine monotherapy. Epilepsia 1999; 40(Suppl): 259","journal-title":"Epilepsia"},{"issue":"4","key":"360510_CR47","first-page":"973","volume":"39","author":"T Duckett","year":"1998","unstructured":"Duckett T, Brigell M, Ruckh S. Electroretinographic changes are not associated with loss of function in pediatric epileptic patients following treatment with vigabatrin. Vis Sci 1998; 39(4): 973","journal-title":"Vis Sci"},{"key":"360510_CR48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1023\/A:1002045223358","volume":"97","author":"GFA Harding","year":"1999","unstructured":"Harding GFA, Robertson KA, Edson AS, Barnes P, Wild J. Visual electrophysiological effect of a GABA transaminase blocker. Doc Ophthalmol 1999; 97: 179\u201388","journal-title":"Doc Ophthalmol"},{"key":"360510_CR49","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0042-6989(68)90041-2","volume":"8","author":"KT. Brown","year":"1968","unstructured":"Brown KT. The electroretinogram: Its components and their origin. Vis Res 1968; 8: 633\u201377","journal-title":"Vis Res"},{"key":"360510_CR50","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0042-6989(87)90002-2","volume":"27","author":"NS Peachey","year":"1987","unstructured":"Peachey NS, Alexander KR, Fishman GA. Rod and cone system contributions to oscillatory potentials: an explanation for the conditioning flash. Vis Res 1987; 27: 859\u201366","journal-title":"Vis Res"},{"key":"360510_CR51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0304-3940(89)90368-6","volume":"98","author":"MJ Neal","year":"1988","unstructured":"Neal MJ, Cunningham JR, Shah MA, Yazulla S. Immunocytochemical evidence that vigabatrin in rats cause GABA accumulation in glial cells of the retina. Neurosci Lett 1988; 98: 29\u201332","journal-title":"Neurosci Lett"},{"key":"360510_CR52","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1097\/00001756-199611040-00055","volume":"7","author":"DV Pow","year":"1996","unstructured":"Pow DV, Rogers M. GABA transamination regulates neuronal glutamate content in the retina. Neuroreport 1996; 7: 2683\u20136","journal-title":"Neuroreport"}],"container-title":["Documenta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1014644307518.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1014644307518\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1014644307518.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T03:57:42Z","timestamp":1753761462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1014644307518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["360510"],"URL":"https:\/\/doi.org\/10.1023\/a:1014644307518","relation":{},"ISSN":["0012-4486","1573-2622"],"issn-type":[{"value":"0012-4486","type":"print"},{"value":"1573-2622","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}